ARID1A regulates DNA repair through chromatin organization and its deficiency triggers DNA damage-mediated anti-tumor immune response
Nucleic Acids Research · 10.06.2024 · 52 (10) · 5698-5719
DOI: 10.1093/nar/gkae233 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 08.04.2024. Verfasst von Ali Bakr und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), INF280, 69120 Heidelberg, Germany. Hauptthemen laut MEDLINE: Chromatin, DNA Repair, DNA-Binding Proteins, Immunity. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Cancer Research Center, German Research Foundation, Erasmus.
Abstract (Originalsprache)
AT-rich interaction domain protein 1A (ARID1A), a SWI/SNF chromatin remodeling complex subunit, is frequently mutated across various cancer entities. Loss of ARID1A leads to DNA repair defects. Here, we show that ARID1A plays epigenetic roles to promote both DNA double-strand breaks (DSBs) repair pathways, non-homologous end-joining (NHEJ) and homologous recombination (HR). ARID1A is accumulated at DSBs after DNA damage and regulates chromatin loops formation by recruiting RAD21 and CTCF to DSBs. Simultaneously, ARID1A facilitates transcription silencing at DSBs in transcriptionally active chromatin by recruiting HDAC1 and RSF1 to control the distribution of activating histone marks, chromatin accessibility, and eviction of RNAPII. ARID1A depletion resulted in enhanced accumulation of micronuclei, activation of cGAS-STING pathway, and an increased expression of immunomodulatory cytokines upon ionizing radiation. Furthermore, low ARID1A expression in cancer patients receiving radiotherapy was associated with higher infiltration of several immune cells. The high mutation rate of ARID1A in various cancer types highlights its clinical relevance as a promising biomarker that correlates with the level of immune regulatory cytokines and estimates the levels of tumor-infiltrating immune cells, which can predict the response to the combination of radio- and immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), INF280, 69120 Heidelberg, Germany.
- Division of Proteomics of Stem Cells and Cancer, German Cancer Research Center (DKFZ), INF581, 69120 Heidelberg, Germany.
- Heidelberg University, Medical Faculty, Heidelberg, Germany.
- German Cancer Consortium (DKTK), INF280, 69120 Heidelberg, Germany.
ORCID-Profile: Ali Bakr, Gianluca Sigismondo, Yunhee Jeong, Dieter Weichenhan, Christoph Plass
Förderung
- German Cancer Research Center
- German Research Foundation
- Erasmus
Zitieren
APA
Bakr, A., Della Corte, G., Veselinov, O., Kelekçi, S., Chen, M. M., Lin, Y. Y., Sigismondo, G., Iacovone, M., Cross, A., Syed, R., Jeong, Y., Sollier, E., Liu, C. S., Lutsik, P., Krijgsveld, J., Weichenhan, D., Plass, C., Popanda, O., & Schmezer, P. (2024). ARID1A regulates DNA repair through chromatin organization and its deficiency triggers DNA damage-mediated anti-tumor immune response. Nucleic Acids Research, 52(10), 5698-5719. https://doi.org/10.1093/nar/gkae233
Vancouver
Bakr A, Della Corte G, Veselinov O, Kelekçi S, Chen MM, Lin YY, et al. ARID1A regulates DNA repair through chromatin organization and its deficiency triggers DNA damage-mediated anti-tumor immune response. Nucleic Acids Research. 2024;52(10):5698-5719. doi:10.1093/nar/gkae233
BibTeX
@article{Bakr2024,
author = {Bakr, Ali and Della Corte, Giuditta and Veselinov, Olivera and Kelekçi, Simge and Chen, Mei-Ju May and Lin, Yu-Yu and Sigismondo, Gianluca and Iacovone, Marika and Cross, Alice and Syed, Rabail and Jeong, Yunhee and Sollier, Etienne and Liu, Chun-Shan and Lutsik, Pavlo and Krijgsveld, Jeroen and Weichenhan, Dieter and Plass, Christoph and Popanda, Odilia and Schmezer, Peter},
title = {ARID1A regulates DNA repair through chromatin organization and its deficiency triggers DNA damage-mediated anti-tumor immune response},
journal = {Nucleic Acids Research},
year = {2024},
volume = {52},
number = {10},
pages = {5698--5719},
doi = {10.1093/nar/gkae233}
}
EUVIMED